Vonapanitase

Drug Profile

Vonapanitase

Alternative Names: PRT 201

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Proteon Therapeutics
  • Class Elastases; Recombinant proteins
  • Mechanism of Action Extracellular matrix protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vascular disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Vascular disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Vascular disorders
  • Phase I Peripheral arterial disorders

Most Recent Events

  • 13 Dec 2016 Adverse events and efficacy data from the phase III PATENCY-1 trial in Vascular disorders released by Proteon therapeutics
  • 01 Nov 2016 Proteon Therapeutics initiates enrolment in a phase I trial for Peripheral arterial disorders in USA (NCT02956993)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Peripheral-arterial-disorders in USA (Intra-arterial, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top